Summit Therapeutics Inc.
SMMT
$25.26
$1.305.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 7.96% | -29.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -177.65% | |||
| Total Operating Expenses | 1.89% | 12.40% | |||
| Operating Income | -1.89% | -12.40% | |||
| Income Before Tax | -2.79% | -8.80% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2.79% | -8.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.79% | -8.80% | |||
| EBIT | -1.89% | -12.40% | |||
| EBITDA | -1.88% | -12.40% | |||
| EPS Basic | -2.65% | -7.24% | |||
| Normalized Basic EPS | -2.70% | -7.23% | |||
| EPS Diluted | -0.45% | -12.00% | |||
| Normalized Diluted EPS | -2.70% | -7.23% | |||
| Average Basic Shares Outstanding | 0.08% | 1.49% | |||
| Average Diluted Shares Outstanding | 0.08% | 1.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||